Solventum Corp
SOLV
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
14% upsideUndervalued by 14% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.80 Billion |
|---|---|
| Enterprise Value | $19.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.94 |
| Beta | 0.72 |
| Outstanding Shares | 174,200,000 |
Return
| Return on Equity | 28.82% |
|---|---|
| Return on Assets | 10.16% |
| Return on Invested Capital | 19.40% |
Valuation & Multiples
| P/E Ratio | 10.41 |
|---|---|
| PEG | -11.5 |
| Price to Sales | 1.82 |
| Price to Book Ratio | 3.05 |
| Enterprise Value to Revenue | 2.41 |
| Enterprise Value to EBIT | 9.55 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 1.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 47.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.41%▼ 72.52% |
|---|---|
| Total Invested | $188.92M▼ 97.75% |
| Investors Holding | 221▼ 665.00% |
ESG Score
No data
About Solventum Corp
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid. Its decisions on reimbursement rates and tax policy directly impact Solventum's profitability, market access, and overall valuation as a healthcare company.
This committee allocates discretionary federal spending. Its subcommittees determine the precise funding for agencies that are major customers (e.g., VA, DoD, NIH) or regulators (e.g., FDA) of Solventum, directly affecting the company's market opportunities and regulatory environment.
This committee directly regulates the FDA, which is the primary regulatory body for medical devices and healthcare products. Its oversight of drug and device approval processes, and funding for NIH, directly impacts Solventum's core business, R&D, and market access.
As a medical technology company, Solventum likely sells products to the Department of Veterans Affairs (VA) hospitals and healthcare systems. This committee's funding decisions directly impact government healthcare contractors and medical device manufacturers serving veterans.